Notably, RN7SL1 is selectively transferred to immune cells via CAR-T cell-derived exosomes, restricting the development of bone marrow-derived suppressor cells and enhancing the immunostimulatory properties of DCs, thus effectively activating melanoma with endogenous CD8+ T cells that reject CAR antigens (78). The gene discussed is CD8A; the disease is melanoma.